Literature DB >> 14699144

Receptor trafficking via the perinuclear recycling compartment accompanied by cell division is necessary for permanent neurotensin cell sensitization and leads to chronic mitogen-activated protein kinase activation.

Mireille Toy-Miou-Leong1, Catherine Llorens Cortes, Alain Beaudet, William Rostène, Patricia Forgez.   

Abstract

Most G protein-coupled receptors are internalized after interaction with their respective ligand, a process that subsequently contributes to cell desensitization, receptor endocytosis, trafficking, and finally cell resensitization. Although cellular mechanisms leading to cell desensitization have been widely studied, those responsible for cell resensitization are still poorly understood. We examined here the traffic of the high affinity neurotensin receptor (NT1 receptor) following prolonged exposure to high agonist concentration. Fluorescence and confocal microscopy of Chinese hamster ovary, human neuroblastoma (CHP 212), and murine neuroblastoma (N1E-115) cells expressing green fluorescent protein-tagged NT1 receptor revealed that under prolonged treatment with saturating concentrations of neurotensin (NT) agonist, NT1 receptor and NT transiently accumulated in the perinuclear recycling compartment (PNRC). During this cellular event, cell surface receptors remained markedly depleted as detected by both confocal microscopy and (125)I-NT binding assays. In dividing cells, we observed that following prolonged NT agonist stimulation, NT1 receptors were removed from the PNRC, accumulated in dispersed vesicles inside the cytoplasm, and subsequently reappeared at the cell surface. This NT binding recovery allowed for constant cell sensitization and led to a chronic activation of mitogen-activated protein kinases p42 and p44. Under these conditions, the constant activation of NT1 receptor generates an oncogenic regulation. These observations support the potent role for neuropeptides, such as NT, in cancer progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14699144     DOI: 10.1074/jbc.M303384200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

Review 1.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

2.  Structure of signaling-competent neurotensin receptor 1 obtained by directed evolution in Escherichia coli.

Authors:  Pascal Egloff; Matthias Hillenbrand; Christoph Klenk; Alexander Batyuk; Philipp Heine; Stefanie Balada; Karola M Schlinkmann; Daniel J Scott; Marco Schütz; Andreas Plückthun
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-22       Impact factor: 11.205

3.  Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcome.

Authors:  Mikaël Agopiantz; Patricia Forgez; Jean-Matthieu Casse; Stéphanie Lacomme; Claire Charra-Brunaud; Isabelle Clerc-Urmès; Olivier Morel; Céline Bonnet; Jean-Louis Guéant; Jean-Michel Vignaud; Anne Gompel; Guillaume Gauchotte
Journal:  Virchows Arch       Date:  2017-08-24       Impact factor: 4.064

4.  Neurotensin-induced proinflammatory signaling in human colonocytes is regulated by β-arrestins and endothelin-converting enzyme-1-dependent endocytosis and resensitization of neurotensin receptor 1.

Authors:  Ivy Ka Man Law; Jane E Murphy; Kyriaki Bakirtzi; Nigel W Bunnett; Charalabos Pothoulakis
Journal:  J Biol Chem       Date:  2012-03-13       Impact factor: 5.157

5.  Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors.

Authors:  Clément Morgat; Véronique Brouste; Adrien Chastel; Valérie Vélasco; Gaétan Macgrogan; Elif Hindié
Journal:  Breast Cancer Res Treat       Date:  2021-10-01       Impact factor: 4.872

Review 6.  NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease.

Authors:  Daniel Martinez-Fong; Michael J Bannon; Louis-Eric Trudeau; Juan A Gonzalez-Barrios; Martha L Arango-Rodriguez; Nancy G Hernandez-Chan; David Reyes-Corona; Juan Armendáriz-Borunda; Ivan Navarro-Quiroga
Journal:  Nanomedicine       Date:  2012-03-07       Impact factor: 5.307

7.  Neurotensin receptor 1 is expressed in gastrointestinal stromal tumors but not in interstitial cells of Cajal.

Authors:  Petra Gromova; Brian P Rubin; An Thys; Christophe Erneux; Jean-Marie Vanderwinden
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

8.  The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression.

Authors:  Sandra Dupouy; Véronique Viardot-Foucault; Marco Alifano; Frédérique Souazé; Geneviève Plu-Bureau; Marc Chaouat; Anne Lavaur; Danielle Hugol; Christian Gespach; Anne Gompel; Patricia Forgez
Journal:  PLoS One       Date:  2009-01-19       Impact factor: 3.240

9.  Dissecting the cell to nucleus, perinucleus and cytosol.

Authors:  Tattym E Shaiken; Antone R Opekun
Journal:  Sci Rep       Date:  2014-05-12       Impact factor: 4.379

10.  Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.

Authors:  Sandra Dupouy; Van Kien Doan; Zherui Wu; Najat Mourra; Jin Liu; Olivier De Wever; Frédérique Penault Llorca; Anne Cayre; Amal Kouchkar; Anne Gompel; Patricia Forgez
Journal:  Oncotarget       Date:  2014-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.